Finance
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company“), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata’s Corporate Controller, Richard Rychlik, will retain the position of Controller.
“We are delighted to welcome David to the Armata team,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “David’s extensive experience and track record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve us well as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to initiate pivotal studies next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections.”
Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company’s acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House’s experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the “SEC“) reporting.
Mr. House’s career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Finance
When should kids start learning about money? Advice from local financial advisor
REDMOND, Wash. — When should kids start learning about money, and preparing for adult expenses like rent, car payments, and insurance?
It’s a question asked recently by an ARC Seattle viewer.
We took the question to Adam Powell, Financial Advisor at Private Advisory Group in Redmond. Powell talked with ARC Seattle co-anchor Steve McCarron to share insights on the right age to form money habits, common financial mistakes parents unknowingly pass down to their children, and practical tips to set kids up for long-term financial success.
Find more ARC Seattle stories on our YouTube page.
BE THE FIRST TO COMMENT
Watch ARC Seattle weekdays from 7 to 10 a.m. and 10 to 11 p.m. on KUNS, The CW Network.
Finance
Soft-saving era? Gen-Z embraces new financial trend that puts experiences over long-term planning
LOS ANGELES (KABC) — Many Gen-Zers are adopting a financial approach that prioritizes quality of life in the present, a trend that’s being called “soft saving.”
Bob Wheeler, a CPA, described the mindset as a shift in how young adults balance their current lifestyle with longterm planning.
“It’s really a financial approach of ‘I want to make sure I have a good quality of life, and I’m thinking about the future,’ but not as much as the present,” Wheeler said.
For many Gen Z consumers, that can mean spending more on experiences – like vacations or concerts – rather than saving for major purchases like a car or home.
Wheeler said the approach can offer emotional benefits.
“I think there are definitely benefits, I mean, less anxiety, feeling like life is what you want it to be, fulfillment, versus saving for later on,” he said.
Still, financial experts caution against ignoring longterm stability. Wheeler encouraged young workers to take advantage of employer-sponsored retirement plans.
“They’re not going to do the max. They’re going to do enough to make sure they’re getting the match from your employer, so maybe they’re doing 3% or 5%. Maybe they’re not maxing out their IRAs. Maybe they’re doing $2,500,” he said.
He also stressed the importance of building an emergency fund, typically enough to cover six months of expenses.
“I want people to enjoy their life now because tomorrow is not promised,” Wheeler said. “I also just really reiterate to them ‘and you need to have some money set aside because we don’t know.’”
But saving for a home may not be practical for everyone. In some places, renting can be cheaper, and tenants avoid maintenance costs.
Copyright © 2026 KABC Television, LLC. All rights reserved.
Finance
Local M&A advisory firm Matrix acquired by banking giant Citizens Financial – Richmond BizSense
Matri x Capital Markets Group is now a division of Citizens Financial Group. (Image Courtesy Citizens Financial Group)
Matrix Capital Markets Group is used to helping businesses line up mergers and acquisitions.
For its latest transaction, the Richmond-based M&A advisory and investment banking firm was itself the subject of the deal.
Matrix was acquired last week by Rhode Island-based banking giant Citizens Financial Group.
Matrix, along with its nearly three dozen employees, including 20 in Richmond, are now operating as a division of Citizens, within the $226 billion bank’s investment banking arm, Citizens JMP Securities.
Financial terms of the deal were not disclosed. It involved an asset purchase that bought out Matrix’s 15 shareholders.
The deal ends Matrix’s 38-year run as an independent firm, a notable streak in an industry where consolidation of smaller firms into larger ones is common.
Matrix was founded in Richmond in 1988 by Scott Frayser and Jeff Moore and has since hit its stride by building a niche in handling deals for companies in the downstream energy and convenience retail sector.
The firm has been run in recent years by president Spencer Cavalier and Cedric Fortemps, co-head of the firm’s largest investment banking team.
Fortemps said Matrix began to search for a larger acquirer last year.
Cedric Fortemps
“The board decided to see if we could find a partner and a transaction that could build on what we’ve built thus far,” Fortemps said.
Matrix enlisted investment banking firm Houlihan Lokey to help in the search and negotiate on its behalf, along with the law firm Calfee as its legal advisor.
Fortemps said Citizen rose to the top of the pack of suitors in part due to JMP Securities’ track record of acquiring smaller firms like Matrix.
“They have acquired four other firms very similar to ours. Seeing the successes they had with those groups… the playbook is really to let the firms continue to operate the way they had,” Fortemps said.
Matrix’s Richmond office in the Gateway Plaza building downtown will continue to operate, as will its second office in Baltimore.
The Matrix brand will continue to be used for the time being but will eventually be phased out.
Fortemps said the firm’s success and particularly its growth in recent years has been fueled by its expertise in working deals for downstream energy clients – such as wholesale fuels distributors, propane and heating oil distributors – and convenience store and gas station chains.
Matrix’s rise in that sector began in 1997, when it hired Tom Kelso, who lived in Baltimore and owned a heating oil fuels distribution business. Kelso, who would eventually serve as the firm’s president prior to Cavalier, had a vision to launch an M&A firm for that industry.
“It took seven to eight years to grow it but eventually we were able to get a reputation of really high quality work and those successes on smaller transactions resulted in us being considered for larger deals,” Fortemps said.
Today, 21of the firm’s 26 investment bankers work on the team that handles deals for those industries. It controls about 40% market share for the M&A market for those sectors, Fortemps said.
The firm closes nearly two dozen transactions a year over the last five years and has closed 500 deals since its inception.
The typical value of its deals is more than $20 million, though the transactions it has closed over the last three years in the energy and convenience retail sectors have grown to $140 million per deal, Matrix said.
Its largest deal to date was closed last year, involving the $1.6 billion acquisition of convenience store chain Giant Eagle.
Matrix also works deals in other industries such as lubricants distribution, automotive after-market suppliers and car washes, as well as outdoor recreation and the marine industry.
After decades of representing buyers and sellers in M&A, Fortemps said the Citizens deal was a new experience for the Matrix team: being the target of the transaction, rather than the ones facilitating it.
“It certainly made me appreciate everything our clients have to go through on the other side of the table,” he said.
-
Wisconsin1 week agoSetting sail on iceboats across a frozen lake in Wisconsin
-
Massachusetts1 week agoMassachusetts man awaits word from family in Iran after attacks
-
Maryland1 week agoAM showers Sunday in Maryland
-
Pennsylvania5 days agoPa. man found guilty of raping teen girl who he took to Mexico
-
Florida1 week agoFlorida man rescued after being stuck in shoulder-deep mud for days
-
Sports6 days agoKeith Olbermann under fire for calling Lou Holtz a ‘scumbag’ after legendary coach’s death
-
Detroit, MI4 days agoU.S. Postal Service could run out of money within a year
-
Miami, FL6 days agoCity of Miami celebrates reopening of Flagler Street as part of beautification project